<SEC-DOCUMENT>0001104659-21-075777.txt : 20210602
<SEC-HEADER>0001104659-21-075777.hdr.sgml : 20210602
<ACCEPTANCE-DATETIME>20210602163018
ACCESSION NUMBER:		0001104659-21-075777
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210526
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210602
DATE AS OF CHANGE:		20210602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inotiv, Inc.
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		21989521

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOANALYTICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19970918
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2118253d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
May 26, 2021&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 14pt">INOTIV,
    INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0-23357 </FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">35-1345024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2701 KENT AVENUE</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WEST LAFAYETTE, INDIANA</P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">47906-1382</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Registrant's telephone number, including area code:
(765) 463-4527</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 34%; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Ticker symbol(s)</FONT></TD>
    <TD STYLE="width: 33%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Shares</FONT></TD>
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">NOTV</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1.01 Entry into a Material Definitive
Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set forth
in Item 2.03 regarding the Amendment is incorporated by reference into this Item 1.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.03 Creation of a Direct Financial Obligation
or an Obligation under an Off-Balance Sheet Arrangement of the Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 26, 2021, Inotiv, Inc.
(the &ldquo;<U>Company</U>&rdquo;) and First Internet Bank (&ldquo;<U>FIB</U>&rdquo;) entered into an amendment (the &ldquo;<U>Amendment</U>&rdquo;)
to the Company&rsquo;s Amended and Restated Credit Agreement (the &ldquo;<U>Credit Agreement</U>&rdquo;) with FIB, dated April 30, 2021,
to, among other things, (i) provide the Company and its subsidiary, Seventh Wave Laboratories, LLC, a new term loan facility to finance
the acquisition and refurbishment of certain real property in Maryland Heights, Missouri (the &ldquo;<U>Construction Term Loan</U>&rdquo;)
which the Company had previously leased, and (ii) grant a lien on such real property in favor of FIB. The original principal amount of
the Construction Term Loan is $4,832,000. Interest on the Construction Term Loan shall accrue at a fixed rate annual of 3.85%. The Construction
Term Loan shall be repaid as follows: (i) on the first day of each month from July 1, 2021 through and including January 1, 2022, principal
payments of $10,000, (ii) thereafter, monthly payments of principal and interest in the amount of $28,623.87, and (iii) a final payment
representing the entire unpaid principal balance and all accrued and unpaid interest thereon and all fees and charges in connection therewith,
shall be due and payable at maturity. The Construction Term Loan has a maturity date of December 26, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which
will be filed with the Company&rsquo;s Quarterly Report on Form 10-Q for the period ended June 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 27, 2021, the Company
issued a press release with respect to the Amendment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and
is incorporated herein by reference. This information shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), or incorporated by reference in any filing under the Securities
Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; width: 5%"><A HREF="tm2118253d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; width: 95%"><A HREF="tm2118253d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated May 27, 2021.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Inotiv, Inc. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: June 2, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Beth A. Taylor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Beth A. Taylor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Vice President - Finance</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2118253d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black"><B><I>Source:</I></B></FONT><I>
Inotiv, Inc. May 27, 2021 08:33 ET</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Inotiv Announces Purchase of St. Louis Facility and Plans to Expand
Capacity</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">WEST LAFAYETTE, Ind., May
27, 2021 (GLOBE NEWSWIRE) -- <B>Inotiv, Inc. (NASDAQ:NOTV) (the &ldquo;Company&rdquo;, &ldquo;We&rdquo;, &ldquo;Our&rdquo; or &ldquo;Inotiv&rdquo;</B>),
a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced
that the Company has completed the purchase of its previously leased St. Louis facility for approximately $4.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In early June 2021, the Company intends
to commence construction on approximately 20,000 square feet of unfinished shell space at the 50,000 square foot facility, expanding the
Company&rsquo;s capacity to serve its client base with more comprehensive and integrated service offerings. The expansion will include
laboratories for increased drug metabolism &amp; pharmacokinetics technology and capability, as well as a new cell and molecular biology
suite capable of delivering in vitro solutions in pharmacology and toxicology. The Company will fund the purchase of the facility and
expansion costs by proceeds from the public offering that the Company completed in April 2021, and a new $4.8 million term loan from First
Internet Bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Robert Leasure, Jr., Inotiv&rsquo;s
President and Chief Executive Officer, said, &ldquo;The purchase and expansion of the St. Louis facility should enable Inotiv to further
capitalize on exciting new growth opportunities deriving not only from expanded capabilities in St. Louis, but also from our recent acquisitions
of Bolder BioPATH, Inc. and HistoTox Labs, Inc. This strategic expansion is also designed to extend Inotiv&rsquo;s reach into earlier
stages of drug discovery, driving increased engagement of our pharmacology and toxicology operations and histopathology services.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>About the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Inotiv, Inc. is a leading
contract research organization specializing in nonclinical and analytical drug discovery and development services. The Company focuses
on developing innovative services supporting its clients&rsquo; discovery and development objectives for improved decision-making and
accelerated goal attainment. The Company&rsquo;s products focus on increasing efficiency, improving data, and reducing the cost of taking
new drugs to market. Visit <FONT STYLE="color: #007DB4"><U>inotivco.com</U></FONT> for more information about the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>This release may contain forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the
market and demand for our products and services, the development, marketing and sales of products and services, changes in technology,
industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact
thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures
taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion
and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities
and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Company Contact</U></B></FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Investor Relations</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inotiv, Inc.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Equity Group Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beth A. Taylor, Chief Financial Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kalle Ahl, CFA</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(765) 497-8381</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212) 836-9614</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #007DB4"><U>btaylor@inotivco.com</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">kahl@equityny.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devin Sullivan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212) 836-9608</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dsullivan@equityny.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "@ 2P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNK:2('^(CC\^E*['9'LM%>8^'?%=SILZ073M+9G@@\E/<?X5Z8CK(BNC!E8
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M'H%X_IG\:['P3H\5MIRZA(@-Q-G:2/NKTX^M>?7A+7LQ/4N:]<T(8T#3\?\
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MO**.P\$_\BXG_71OZ5T5<[X)_P"1<3_KHW]*Z*NE'.]RAKG_ " =0_Z]W_\
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M%% !1110 4444 %(RJZE64,IZ@C(-+10 BJ%4*H  Z =J6BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
